drugset
drugset / Trial / NCT06520540

HDM1002 Tablets in Chinese Overweight and Obese Adult Subjects

NCT06520540 ↗

Phase 1 Not yet recruiting 72 enrolled Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

• To assess the safety of multiple oral doses of HDM1002 tablets under different titrations in Chinese overweight and obese adult subjects.

Timeline

Start
2024-07-28
Primary completion
2024-11-30
Completion
2024-12-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator HDM1002 Unknown 100 mg Oral
Comparator HDM1002 Unknown 200 mg Oral
Comparator HDM1002 Unknown 400 mg Oral

Indications

No indication recorded.